Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| As you can see, we strongly believe in the potential of our technology and what it could mean for global public health and are excited for the opportunities that lie before us |
| Across Vaxart, we are excited about the potential of our norovirus vaccine program |
| We believe these data we have seen to date show promise for this vaccine candidate and more broadly, our vaccine platform |
| So we're very excited about that |
| The clinical data we have generated thus far across our multiple programs suggests that mucosal vaccination could provide several important advantages; broader, cross-variant protection, reduction in viral transmission, more durable protection, and a broader immune response through the activation of both serum and mucosal immunity |
| We made significant clinical progress in the second quarter, highlighted by the positive preliminary top line data that we reported from the Phase 2 dose ranging study for our bivalent norovirus oral vaccine candidate |
| During the second quarter, we are pleased to report positive preliminary top line results from our Phase 2 dose ranging study for our bivalent norovirus oral vaccine candidate within our stated timeline |
| To date, Vaxart’s COVID-19 vaccine construct has demonstrated a favorable immune profile |
| The results also demonstrate that the bivalent norovirus vaccine candidate was well tolerated with a favorable safety profile that included no vaccine-related serious adverse events or SAEs, and no dose limiting toxicity |
| As you mentioned, we're very fortunate to move this study forward and to be able to deliver the data on time |
| Vaxart believes a cross-protective vaccine could improve our ability to fight future pandemics and is committed to that effort |
| Certainly, if we stay on track with what we've seen in previous studies and note robust responses from mucosal or cell-based assays, that would be very encouraging |
| We're very encouraged by the U.S |
| So we're fairly pleased that the data from that study to date is consistent with previous norovirus study results |
| And because of that, I think we’ll take a look at executing challenges in the future should they be needed, both when the challenge model is available and we think that we have the best opportunity to recruit individuals to move forward in the study |
| We believe our norovirus vaccine program has the potential to address this myth and the significant tremendous disease burden that norovirus carries |
| government's proactive approach to pandemic preparedness and strongly support global efforts to get ahead of the next global health crisis |
| Oral pill vaccines would allow us to vaccinate a lot more people faster, more easily and painlessly than we are doing today with injectable vaccines |
| However, there are some studies that suggest that if you vaccinate children, you can also improve the health of adults |
| This vision is the future of vaccination that we are working so hard to achieve |
| Once we've assessed that data, I think we can make a stronger decision moving forward |
| The potential advantages of oral pill vaccines are so fundamental that making them a reality could radically change how we think about vaccines and vaccination globally |
| We continue to believe in the potential of our bivalent norovirus candidate as we proceed toward a BLA submission |
| Congratulations on the quarterly progress |
| Vaxart continues to make progress on this program |
| Looking ahead, we have two important clinical milestones this year, and we remain on track to achieve them both |
| As we cope with a post emergency phase of the pandemic, we must build stronger defenses against future infectious diseases and other stress we face [ph] |
| And this is a very important distinctive feature of our platform |
| And as you can appreciate, there are advantages and disadvantages to partnering and going it alone |
| As we described in detail in our July announcement, the preliminary results of the trial showed robust serum immune responses across all doses at day 29 relative to day one |
| Statement |
|---|
| Actual results could differ materially from those discussed in these forward-looking statements due to a number of important factors, including uncertainty inherent in the clinical development and regulatory process, and other risks described in the Risk Factors section of Vaxart's most recently filed Annual Report on Form 10-K and also on other periodic reports filed with the SEC |
| So I think that there is some seasonality to the traditional spread of norovirus, but it is a viral infection that impacts people year round |
| Norovirus is a significant public health issue in developed countries, and there is no approved vaccine |
| That said, there are outbreaks of norovirus that continue really on any month of the year |
Please consider a small donation if you think this website provides you with relevant information